The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy

March 12, 2025 updated by: Du Lingzhi

The CT-based Deep Learning Model Outperforms Traditional Anatomical Classification Models in Preoperatively Predicting Complications and Risk Grade in Partial Nephrectomy

The investigators combine radiomics and deep learning to analyze the lesions more thoroughly, aiming for a more accurate prediction of complications in partial nephrectomy, and compare this approach with traditional models.

Study Overview

Status

Completed

Detailed Description

In this study, patients diagnosed with renal cell carcinoma or renal cyst who underwent partial nephrectomy across multiple centers was included. And the participants were excluded if they had (a) missing or unavailable imaging data or (b) no available enhanced CT images. The cohort was divided into training and test sets at a 7:3 ratio. After that, the radiomics features were extracted from the images, and lasso regression was used to select features. Then a deep learning model was developed to predict complications and risk grades and compared with traditional classification models (RENAL and PADUA), demonstrating superior applicability.

Study Type

Observational

Enrollment (Actual)

1474

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Xuhui District
      • Shanghai, Xuhui District, China, 200032
        • Name: Zhongshan Hospital Fudan University, Location: 180th Fenglin Road, Xuhui District, Shanghai, China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population includes patients diagnosed with renal cell carcinoma or renal cyst who underwent partial nephrectomy in the participated centers. Clinical and imaging data were retrospectively collected from medical records, including demographic characteristics (age, gender, BMI), tumor location (left or right kidney), surgical details (surgical approach, ischemia time), and perioperative complications.

Patients were included based on the availability of complete clinical, surgical, and imaging data. Exclusion criteria comprised individuals with missing or unavailable imaging data, or no available enhanced CT images. The study aims to combine CT-based radiomics features and clinical features to develop a deep learning model to predict perioperative complications of partial nephrectomy, and compare with traditional anatomical classification models.

Description

Inclusion Criteria:

  • Clinical diagnosis of renal cell carcinoma or renal cyst
  • Underwent partial nephrectomy between June 2014 and July 2024

Exclusion Criteria:

  • Missing or unavailable imaging data
  • No available enhanced CT images

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Complication 1
Patients who experienced perioperative complications during the partial nephrectomy
Complication 0
Patients who didn't experience perioperative complications during the partial nephrectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
whether complications occurred
Time Frame: perioperatively
Retrospectively review the medical record system to determine whether patients developed postoperative complications.
perioperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patients' risk grade
Time Frame: perioperatively
Based on the widely recognized Clavien-Dindo classification (CDC) system for surgical complications, these complications were categorized into four grades: Grade I, II, III, and IV. Risk grade was assigned accordingly: "no risk" is defined as no complications occurred, "grade low" is defined as the highest level of complication being Grade I, "grade moderate" is defined as the highest level of complication being Grade II, and "grade high" is defined as complications of Grade III or higher, which are life-threatening.
perioperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2024

Primary Completion (Actual)

December 31, 2024

Study Completion (Actual)

February 28, 2025

Study Registration Dates

First Submitted

March 8, 2025

First Submitted That Met QC Criteria

March 12, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 12, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Clinical data and extracted radiomics feature data, excluding patient information.

IPD Sharing Time Frame

Within six months after publication in the journal.

IPD Sharing Access Criteria

The data supporting this study are available from the enrolled institutions, but restrictions apply to their availability due to privacy reasons. Data can be accessed upon reasonable request from the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Cell Carcinoma (RCC)

Subscribe